TABLE 4.
Details of Venous Thromboembolic Events in NBA Playersa
| Type of VTE | Treatment | Risk Factors Identified | Time Missed From Play, mo | Year of Event | NBA Team |
|---|---|---|---|---|---|
| LE DVT | Anticoagulation therapy (Coumadin 1 wk, heparin daily injections after, aspirin remainder of season) | Previous incidences (heart episode [1996], thrombophlebitis [1989]) | 0.43 | 2001 | Houston Rockets |
| Anticoagulation therapy | Previous DVT/PE | CE | 2016b | Miami Heat | |
| PE | Anticoagulation therapy | 3.00 | 2015 | Brooklyn Nets | |
| Surgical removal, anticoagulation therapy (3 mo) | Postsurgical complication | 9.37 | 2013 | Cleveland Cavaliers | |
| DVT and PE | Anticoagulation therapy (Xarelto 3 mo), followed by continual aspirin therapy | 8.30 | 2015b | Miami Heat |
aCE, career ending; DVT, deep vein thrombosis; LE, lower extremity; NBA, National Basketball Association; PE, pulmonary embolism; VTE, venous thromboembolism.
bAthlete with recurrent VTE.